Skip to main content

Year: 2025

EverCommerce Announces Fourth Quarter and Full Year 2024 Financial Results

DENVER, March 13, 2025 (GLOBE NEWSWIRE) — EverCommerce Inc. (“EverCommerce” or the “Company”) (NASDAQ: EVCM), a leading service commerce platform, today announced financial results for the quarter and year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsRevenue of $175.0 million, an increase of 3.3% compared to $169.4 million for the quarter ended December 31, 2023. Pro forma revenue, which excludes fitness solutions, increased approximately 7.0% compared to $163.6 million for the quarter ended December 31, 2023. Subscription and transaction fee revenue of $139.0 million, an increase of 4.2% compared to $133.5 million for the quarter ended December 31, 2023. Pro forma subscription and transaction fee revenue, which excludes fitness solutions, increased approximately 8.9% compared to $127.7...

Continue reading

Pyxis Tankers Announces Financial Results for the Three Months and Year Ended December 31, 2024

Maroussi, Greece, March 13, 2025 – Pyxis Tankers Inc. (Nasdaq Cap Mkts: PXS), (the “Company” or “Pyxis Tankers”), an international shipping company, today announced unaudited results for the three months and year ended December 31, 2024. For the three months ended December 31, 2024, our revenues, net were $12.0 million. For the same period, our time charter equivalent (“TCE”) revenues were $7.9 million, a decrease of $4.0 million, or 33.6%, over the comparable period in 2023. Our Adjusted net income for the fourth quarter, 2024 was $0.3 million with Adjusted income per common share of $0.03 basic and diluted. Our Adjusted EBITDA for the three months ended December 31, 2024, was $3.3 million, a decrease of $4.5 million over the comparable period in 2023. On October 20, 2024, the Company fully redeemed all the remaining outstanding 303,171...

Continue reading

The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results

– Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 – – Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended December 31, 2024. The results of operations of the corporate clinics business segment have been classified as discontinued operations for all periods presented, and the following figures represent continuing operations unless otherwise stated. Q4 2024 Financial HighlightsGrew revenue to $14.4 million, up 14% compared to Q4 2023. Reported net income from continuing operations of $986,000, compared to net loss from continuing operations...

Continue reading

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free Expanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseases Continued operational execution with strengthened strategic focus on aligning resources in an effort to drive high-impact programs forward Maintaining cash position to support operations and achievement of anticipated development milestones throughout 2025 and into 2026NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported...

Continue reading

Zumiez Inc. Announces Fiscal 2024 Fourth Quarter Results

Fourth Quarter Comparable Sales Increased 5.9%Fourth Quarter Gross Margin Increased 190 Basis Points to 36.2%Fourth Quarter Earnings Per Share Improved to $0.78 from ($1.73)First Quarter-To-Date Comparable Sales up 4.3%, Led by North America Up 6.4%Board Approves New Stock Repurchase Authorization LYNNWOOD, Wash., March 13, 2025 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the fourth quarter and year ended February 1, 2025. Net sales for the fourth quarter ended February 1, 2025 (13 weeks) decreased 0.9% to $279.2 million from $281.8 million in the fourth quarter ended February 3, 2024 (14 weeks). Comparable sales for the thirteen weeks ended February 1, 2025 increased 5.9%. Net income in the fourth...

Continue reading

Karat Packaging Reports Fourth Quarter and Full Year 2024 Financial Results

— Robust Growth, Including Record Full Year Gross Margin, as Business Continues to Expand — CHINO, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 HighlightsNet sales of $101.6 million, up 6.3 percent, from $95.6 million in the prior-year quarter. Gross profit of $39.8 million, up 16.8 percent, from $34.1 million in prior-year quarter. Gross margin of 39.2 percent versus 35.7 percent in the prior-year quarter. Net income of $5.9 million, up 40.3 percent, from $4.2 million in the prior-year quarter. Net income margin of 5.8 percent versus...

Continue reading

HF Foods Reports Fourth Quarter and Full Year 2024 Financial Results

Net Revenue Increased 8.7% and 4.6% for the Fourth Quarter and Full Year 2024, Respectively Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading food distributor to Asian restaurants across the United States, reported its unaudited financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial ResultsNet revenue increased 8.7% to $305.3 million compared to $280.9 million in the prior year period. Gross profit decreased 0.2% to $52.2 million compared to $52.3 million in the prior year period. Gross profit margin decreased to 17.1% from 18.6% in the prior year period. Net loss of $43.9 million, mainly due to goodwill impairment of $46.3 million,...

Continue reading

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the fourth quarter and full year ended December 31, 2024,...

Continue reading

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient Enrollment Lymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025 Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027ALLO-329 in Autoimmune Disease (AID)Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in Rheumatology Trial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025ALLO-316 in Renal Cell Carcinoma (RCC)Presented Positive Phase 1 Data Highlighting Meaningful Response Rates in Patients with Advanced Renal Cell Carcinoma and the Potential of the CD70 Dagger® Technology...

Continue reading

Blum Holdings Inc. Releases 2024 Annual Report: Executive Summary

DOWNEY, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company and cannabis operator, is proud to announce the release of its “2024 Annual Report: Executive Summary”. “The Executive Summary highlights Blüm’s significant financial and operational transformation over the past year,” said Sabas Carrillo, Chief Executive Officer of Blüm Holdings. “Through strategic restructuring, substantial debt reduction, and a disciplined focus on core operations, we have meaningfully strengthened our financial foundation. Despite ongoing industry challenges, we believe our ability to streamline operations, optimize our asset portfolio, and enhance financial efficiency has positioned us for long-term growth. Additionally,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.